Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 2/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12709258 | 0.90 | HSD17B1 (0.35) | F10HSD17B1PELI1HSD17B10 | |
| SCHEMBL1277164 | 0.90 | BACE1 (0.38) | F10HSD17B1PELI1HSD17B10KDM4E | |
| SCHEMBL1277392 | 0.89 | HSD17B1 (0.36) | F10HSD17B1PELI1HSD17B10FYN | |
| SCHEMBL1277366 | 0.89 | HSD17B1 (0.33) | F10HSD17B1PELI1HSD17B10FYN | |
| SCHEMBL1277316 | 0.87 | MGAM (0.39) | HSD17B10ABCG2 | |
| SCHEMBL1277083 | 0.86 | BAZ2B (0.36) | F10HSD17B1PELI1FYN | |
| SCHEMBL1277438 | 0.86 | SLC9A3 (0.40) | F10HSD17B1PELI1KDM4EMAPT | |
| SCHEMBL1277265 | 0.85 | DHODH (0.39) | F10HSD17B1PELI1FYNUSP7 | |
| SCHEMBL1277277 | 0.85 | BACE1 (0.40) | F10HSD17B1ABCG2PRSS1 | |
| SCHEMBL1277331 | 0.83 | HDAC8 (0.38) | PELI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | F10 4727/4885HSD17B1 2621/4885PELI1 4376/4885 |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | F10 4727/4885HSD17B1 2621/4885PELI1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.